Windward Bio AG

Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The company is led by a highly experienced team of biopharmaceutical executives with deep discovery, development, and commercialization expertise. The company is advancing a potential best-in-class thymic stromal lymphopoietin (TSLP) monoclonal antibody into phase 2 development and creating novel, long-acting bispecific programs for immunological diseases.